- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Potentially Resectable ALK Positive Non-Small Cell Lung Cancer in Japan
Total 400 results
-
Masahiro TsuboiEli Lilly and Company; Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢAJapan
-
Tomoshi TsuchiyaCompleted
-
Hamamatsu UniversityCompletedNon-small Cell Lung CancerJapan
-
Shiga UniversityTokyo UniversityCompletedNon-small Cell Lung CancerJapan
-
Shiga UniversityTokyo UniversityCompletedNon-small Cell Lung CancerJapan
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Tokyo UniversityHuman Genome Center, Institute of Medical Science, University of TokyoUnknownNon Small Cell Lung CancerJapan
-
Tokyo UniversityShionogi; National Cancer Center Hospital East; Hokkaido University; Fukushima... and other collaboratorsUnknownNon-small- Cell Lung CancerJapan
-
Tokyo UniversityHuman Genome Center, Institute of Medical Science, University of TokyoUnknownNon Small Cell Lung CancerJapan
-
National Hospital Organization Nagoya Medical CenterMerck Sharp & Dohme LLC; Central Japan Lung Study GroupActive, not recruitingNon-squamous Non-small-cell Lung Cancer | Cancer, LungJapan
-
PfizerCompletedALK-positive Non-small-cell Lung CancerJapan
-
Fukushima Medical UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompleted
-
Shiga UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedNon-small Cell Lung CancerJapan
-
TakedaRecruitingNon-small Cell Lung Cancer (NSCLC)Japan
-
Shiga UniversityCompletedNon-small Cell Lung CancerJapan
-
Novartis PharmaceuticalsCompleted
-
Kyowa Kirin Co., Ltd.CompletedAdvanced/Recurrent Non-small-cell Lung CancerJapan
-
Kyowa Kirin Co., Ltd.CompletedNon-small-cell Lung CancerJapan
-
Kobe City General HospitalTerminatedAdvanced Non-small Cell Lung CancerJapan
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
R-PharmCompletedNon-small Cell Lung Cancer (NSCLC)Japan
-
Kyowa Kirin Co., Ltd.Completed
-
Fukushima Medical UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedNon Small Cell Lung CancerJapan
-
PfizerCompletedSystemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except LeukemiaUnited States, Korea, Republic of, Australia, Japan
-
Eisai Co., Ltd.CompletedNon-small-cell Lung CancerJapan
-
Astellas Pharma Global Development, Inc.Terminated
-
Daiichi Sankyo Co., Ltd.TerminatedNon Small Cell Lung CancerJapan
-
Kyoto UniversityTranslational Research Center for Medical Innovation, Kobe, Hyogo, JapanUnknown
-
Astellas Pharma IncTerminatedNon-small Cell Lung CancerJapan, Korea, Republic of, Taiwan
-
Hamamatsu UniversityCompletedNon-Small Cell Lung CancerJapan
-
Eli Lilly and CompanyCompletedNon Small Cell Lung CancerJapan
-
Eli Lilly and CompanyCompletedNon-small Cell Lung CancerJapan
-
Shiga UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedNon-Small Cell Lung CancerJapan
-
Bristol-Myers SquibbCompletedNon-Small Cell Lung CancerJapan
-
Juntendo UniversityMerck Sharp & Dohme LLCActive, not recruitingNon-squamous Non-small-cell Lung Cancer | EGFR Activating MutationJapan
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdCompleted
-
Eli Lilly and CompanyCompletedNon-small Cell Lung Cancer MetastaticJapan
-
Gunma UniversityJ~pharmaCompletedNon-Small Cell Lung Cancer | AngiogenesisJapan
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
Bristol-Myers SquibbOno Pharma USA IncCompleted
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
-
Eli Lilly and CompanyCompletedSquamous Non-small Cell Lung CancerJapan
-
Novartis PharmaceuticalsRecruitingNon-small Cell Lung CancerUnited States, Korea, Republic of, Spain, Japan, Germany, Switzerland
-
Novartis PharmaceuticalsCompletedNon-Small-Cell Lung CancerJapan
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingLung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung CancerPhilippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCActive, not recruiting
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCCompletedStage IV Non-Small Cell Lung CancerSpain, United States, France, Japan